Mineralys Therapeutics (MLYS) Common Equity (2022 - 2026)
Mineralys Therapeutics (MLYS) recorded Common Equity of $503.78 million in Q3 2026, down 12.6% from $576.43 million a year earlier and down 8.6% from the prior quarter.
Powered by 
Analysis
Mineralys Therapeutics (MLYS) Common Equity (2022 - 2026) Analysis & Trends
At the end of FY2025, Mineralys Therapeutics reported Common Equity of $646.69 million, up 238.1% from FY2024.
- Across earlier years, Common Equity came in at $191.26 million in FY2024 (-20.7%), $241.15 million in FY2023 and -$52.27 million in FY2022.
- The Q3 2026 figure is the lowest quarterly Common Equity since Q2 2025.
- On a year-over-year basis, Common Equity rose in six of the last eight quarters, with growth averaging 65.4%.
- Peak year-over-year performance for Common Equity in the last five years was growth of 238.1% in Q4 2025, against a decline of 20.7% in Q4 2024 at the low end.
- Per Business Quant, the preceding three quarters came in at $550.92 million (Q2 2026), $638.14 million (Q1 2026) and $646.69 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 40.27 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 81.53 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | -4.58 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 44.95 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 41.95 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | 50.37 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 14.35 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 13.04 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 89.30 Bn |
| 10 | Mineralys Therapeutics | 1.42 Bn | -1.17 Bn | - | 503.78 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 503.78 Mn |
| Jun 30, 2026 | 550.92 Mn |
| Mar 31, 2026 | 638.14 Mn |
| Dec 31, 2025 | 646.69 Mn |
| Sep 30, 2025 | 576.43 Mn |
| Jun 30, 2025 | 313.55 Mn |
| Mar 31, 2025 | 341.56 Mn |
| Dec 31, 2024 | 191.26 Mn |
| Sep 30, 2024 | 236.93 Mn |
| Jun 30, 2024 | 290.10 Mn |
| Mar 31, 2024 | 328.05 Mn |
| Dec 31, 2023 | 241.15 Mn |
| Sep 30, 2023 | 264.01 Mn |
| Jun 30, 2023 | 285.01 Mn |
| Mar 31, 2023 | 295.88 Mn |
| Dec 31, 2022 | -52.27 Mn |
| Sep 30, 2022 | -43.41 Mn |
| Jun 30, 2022 | -36.93 Mn |
| Mar 31, 2022 | -30.48 Mn |
API Access
Mineralys Therapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=MLYS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "MLYS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=MLYS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();